Drug Research
There Is More To VEXAS Syndrome Than Previously Perceived
As per a recent study that was published in JAMA, a not so well-known syndrome with high mortality has a much higher prevalence than it was thought. The syndrome called VEXAS was first identified in 2020 in patients who...
Drug Research
Anti-Cancer Chemistry For Skullcap Fit For Modern Drugs
A collaboration between Chinese researchers and UK researchers has led to the unlocking of facilities related to evolutionary secrets that help the medicinal herb called barbed skullcap develop cancer-fighting compounds.
The CEPAMS partnership made use of DNA sequencing tech to...
IT & Data Management
Cancer Mutation Analysis Through AI- A Strong Step Forward
When single-cell data is combined with a self-learning algorithm, it is a revelation as to how structural changes can go on to trigger cancer. This new methodology can indeed pave the road for cancer treatments that are personalised in...
Drug Research
Strict Steps In Supply Chain Against Contamination By WHO
The World Health Organization has urged regulators, suppliers, as well as medicine manufacturers to take strict steps against medicines in the supply chain that are contaminated. This is due to the recent instances of over-the-counter cough syrups which had...
News
Top 6 Tips to Prevent Urinary Tract Infection
A urinary tract infection (UTI) is an infection that spreads to your urine system. Mostly, the lower urinary system's bladder and urethra are impacted. There will probably be a constant urge to urinate if you have a UTI. Urinary...
Drug Research
Novel Method On Large DNA Sequences Insertion Successful
Recent work by researchers at Massachusetts General Hospital (MGH) in the US has improved the accuracy of inserting long DNA fragments into genomes.
This method might be used to introduce an entire wild-type or normal substitute gene, acting as a...
News
BeiGene’s Brukinsa receives UK marketing authorisations to treat cancers
BeiGene, a global biotechnology company, announced that the U.S. FDA has approved its Bruton’s tyrosine kinase inhibitor (BTKi) BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
“With four US approvals...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read